文献速递免疫规划

健康老年人单剂四抗原或三抗原金黄色葡萄球菌疫苗的安全性、耐受性与免疫原性:一项随机试验结果

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
PubMed 文献 · Vaccine · 2016-11-17

这项双盲、申办方非盲、安慰剂对照的1/2期研究在284名65-85岁健康成人中评价单剂四抗原(SA4Ag)或三抗原(SA3Ag)金黄色葡萄球菌疫苗的安全性、耐受性与免疫原性。结果显示两种疫苗均安全诱导快速且稳健的功能性免疫应答,SA4Ag对rP305A呈剂量水平应答,支持进一步开发SA4Ag用于预防成人(至85岁)金黄色葡萄球菌病。

要点

  • 在65-85岁健康成人中,单剂SA4Ag和SA3Ag安全诱导了快速且稳健的功能性免疫应答。
  • SA4Ag对rP305A呈剂量水平应答,第29天cLIA滴度最高上升13倍。
  • 本研究中未发现安全性问题,且不良事件未随rP305A剂量水平升高而增加。

核心结论

  • 在65-85岁健康成人中单剂接种SA4Ag和SA3Ag可安全诱导快速且稳健的功能性免疫应答,支持进一步开发SA4Ag用于预防成人(至85岁)金黄色葡萄球菌病。

研究设计与样本

  • 双盲、申办方非盲、安慰剂对照的1/2期研究,284名65-85岁健康成人随机接受单剂三种rP305A剂量递增的SA4Ag制剂之一、SA3Ag或安慰剂。
  • SA3Ag含荚膜多糖血清型5和8(CP5和CP8)与无毒突变型白喉毒素(CRM197)偶联物及重组凝聚因子A(ClfA);SA4Ag在此基础上增加重组锰转运蛋白C(rP305A或MntC);两种疫苗均未加佐剂。
  • 免疫功能采用调理吞噬活性(OPA)杀伤试验和纤维蛋白原结合抑制(FBI)试验测定,免疫原性另用竞争性Luminex®免疫分析(cLIA)评估;T细胞应答在小子组中用细胞内细胞因子染色(ICS)试验测定。

主要发现

  • 在健康老年人中所有抗原均诱导快速且稳健的功能性免疫应答,高比例主动疫苗接种者在第29天达到各抗原预设抗体阈值。
  • SA4Ag对rP305A呈剂量水平应答,第29天cLIA滴度最高上升13倍。
  • 第29天OPA试验显示,使用表达CP5和CP8的金黄色葡萄球菌菌株,功能性滴度分别上升>50倍和>20倍。
  • T细胞细胞因子应答未显著高于背景水平。
  • 本研究人群中未发现安全性问题,且不良事件未随rP305A剂量水平升高而增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The decline in immune function with age is a challenge to vaccine development. Following an initial study in adults aged 18-64years, this study evaluated the safety and immunogenicity of Staphylococcus aureus (S. aureus) 4-antigen (SA4Ag) and 3-antigen (SA3Ag) vaccine in older adults. SA3Ag included capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to the nontoxic mutant form of diphtheria toxin (CRM197) and a recombinant version of clumping factor A (ClfA). SA4Ag included these antigens, with the addition of a recombinant manganese transporter C (rP305A or MntC). Both vaccines were unadjuvanted. METHODS: In this double-blind, sponsor-unblinded, placebo-controlled, phase 1/2 study, 284 healthy adults (aged 65-85years) were randomised to receive a single dose of one of three formulations of SA4Ag with escalating dose levels of rP305A, SA3Ag, or placebo. Functional immune responses were measured using opsonophagocytic activity (OPA) killing and fibrinogen-binding inhibition (FBI) assays; immunogenicity was also assessed using a competitive Luminex® immunoassay (cLIA). T-cell responses were measured in a small subgroup of subjects using intracellular cytokine staining (ICS) assays. RESULTS: The results demonstrated rapid and robust functional immune responses to all antigens in healthy older adults. A high proportion of active vaccine recipients met the pre-defined antibody thresholds for each antigen at Day 29. SA4Ag elicited a dose-level response to rP305A with up to a 13-fold rise in cLIA titres at Day 29. Opsonophagocytic activity (OPA) assays showed >50- and >20-fold rises in functional titres using S. aureus strains expressing CP5 and CP8, respectively, at Day 29. T-cell cytokine responses were not substantially above background levels. There were no safety concerns in this study population and no increases in adverse events with higher rP305A dose levels. CONCLUSIONS: Single-dose vaccination of SA4Ag and SA3Ag in healthy adults aged 65-85years safely induced rapid and robust functional immune responses, supporting further development of SA4Ag for the prevention of S. aureus disease in adults up to age 85years. TRIAL REGISTRATION NUMBER: NCT01643941.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Creech CB, Frenck RW, Sheldon EA, et al. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Vaccine. 2016. PMID: 27866765. doi:10.1016/j.vaccine.2016.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。